UCB announced that The Lancet has published two articles detailing 24-week results from the phase 3 BE OPTIMAL study and 16-week results from the phase 3 BE COMPLETE study, evaluating the efficacy and safety of bimekizumab (Bimzelx®) in the treatment of adults with active...
The Lancet publishes results from two bimekizumab phase 3 studies in psoriatic arthritis
